Comparative renoprotection: Sacubitril/valsartan versus ACEI or ARB -A systematic review and meta-analysis

• DOI: 10.4314/tjpr.v23i2.27
• Publication Date: 2024-03-14T11:26:57Z
• Authors: Jingtao Yang; Chen Li; Cong Lu; Jun Cheng
• Keywords: Sacubitril, Valsartan

Purpose: To evaluate the renoprotective effect of sacubitril/valsartan (Sac/Val) against angiotensin-converting enzyme inhibitors (ACEI)/angiotensin receptor blockers (ARB). 
 Methods: Following PRISMA guidelines, a thorough search PubMed, Embase, Web Science, and Cochrane Library was performed up to May 18, 2023. Eligibility criteria included prospective, randomized, controlled trials comparing sac/Val ACEI/ARB with regard renal outcomes. Data extraction quality assessment were undertaken independently by two reviewers. Fixed or random effects models used depending on heterogeneity among studies. Subgroup analyses based presence absence heart failure. Results: Eleven varied patient populations clinical settings included. The meta-analysis revealed that Sac/Val exhibited significantly reduced risk function decline compared (Risk Ratio (RR) = 0.86, 95 % Confidence Interval (CI) (0.78, 0.96), p 0.016). analysis showed significant in patients failure (RR 0.84, CI (0.75, 0.94), 0.011), but not non-heart 1.04, (0.80, 1.37), 0.66). Conclusions: This systematic review suggest confers substantial ACEI/ARB, particularly patients. However, further research is required elaborate full potential as nephroprotective agent.